KBC Group NV Acquires 56,580 Shares of LivaNova PLC (NASDAQ:LIVN)

KBC Group NV increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 130.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 99,928 shares of the company’s stock after buying an additional 56,580 shares during the quarter. KBC Group NV’s holdings in LivaNova were worth $4,628,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Squarepoint Ops LLC increased its position in shares of LivaNova by 100.5% during the 2nd quarter. Squarepoint Ops LLC now owns 11,173 shares of the company’s stock valued at $613,000 after purchasing an additional 5,601 shares during the last quarter. AQR Capital Management LLC increased its holdings in LivaNova by 0.7% during the second quarter. AQR Capital Management LLC now owns 129,871 shares of the company’s stock worth $7,103,000 after buying an additional 930 shares during the last quarter. Central Pacific Bank Trust Division purchased a new stake in LivaNova during the third quarter worth about $178,000. Diversified Trust Co raised its position in LivaNova by 7.9% in the third quarter. Diversified Trust Co now owns 15,007 shares of the company’s stock worth $788,000 after acquiring an additional 1,105 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. boosted its stake in LivaNova by 11.8% in the third quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 19,000 shares of the company’s stock valued at $998,000 after acquiring an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Down 0.2 %

Shares of LIVN stock opened at $50.64 on Friday. The company has a market capitalization of $2.75 billion, a PE ratio of 120.57 and a beta of 1.01. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47. The business’s fifty day moving average is $49.05 and its 200 day moving average is $49.97. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LIVN shares. Mizuho lowered their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Tuesday. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 23rd. Finally, Robert W. Baird raised their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, LivaNova presently has a consensus rating of “Buy” and an average price target of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.